Study of LY4152199 for Lymphoma That Returned or Didn't Respond
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with follicular lymphoma or diffuse large B-cell lymphoma.
- You are able to care for yourself and are up and about (ECOG score 0 or 1).
- Your doctor expects you to live at least 12 more weeks.
- You have at least one measurable tumor or bone marrow involvement (for lymphoma).
- Your organs (like kidneys, liver, blood cells) are working well enough for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This study tests an experimental drug (GSK5926371) for people with a type of lymphoma (B-cell NHL) that has come back or not responded to earlier treatments. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This Phase 2 trial tests two targeted antibody medicines—loncastuximab tesirine and mosunetuzumab—in people whose diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3B has come back or did not respond. It aims to shrink lymphoma that has measurable disease and has specific markers (CD19 and CD20) on tumor cells.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.